Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.
The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.
Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.
The companies will offer customers access to their technologies and services for cancer image analysis and tissue-based biomarker research and development.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.
NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.
NEW YORK (GenomeWeb) – Definiens announced today that it has raised €15 million ($20.4 million) in a private round of financing that will support the firm's efforts to expand its business into digital tissue diagnostics.
NEW YORK (GenomeWeb News) – Definiens and Metamark Genetics today announced a multiyear agreement for use of Definiens' image analysis product for Metamark's prostate cancer prognostic test.
Vermillion said this week that at its annual meeting on March 21, shareholders elected Robert Goggin to the company's board of directors.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.